 |
| Anno I | Numero 3 | Luglio 2016 |
| Comitato scientifico editoriale: Massimo Di Maio, Silvia Novello Editore: Intermedia – Direttore Responsabile: Mauro Boldrini |
|
Cari colleghi, |
| Notizie dalla ricerca |
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-CellLung Cancer |
| Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced NSCLC was evaluated in the phase I, multicohort, Checkmate 012 trial. Fifty-two patients received nivolumab 3 mg/kg intravenously every 2 weeks until progression or unacceptable toxicity; postprogression treatment was permitted per … |
| Continua a leggere |
| Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial |
| Immunotherapy targeting the PD-1 axis has activity in several tumour types. We aimed to establish the activity and safety of the PD-1 inhibitor pembrolizumab in patients with untreated brain metastases from melanoma or non-small-cell lung cancer (NSCLC). In this non-randomised, open-label, phase 2 trial, we enrolled patients aged 18 years or older with melanoma or NSCLC with untreated brain metastases from the Yale Cancer Center. Patients had at least one untreated or progressive brain metastasis between 5 … |
| Continua a leggere |
| Management of toxicities of immune checkpoint inhibitors |
| Immune checkpoint inhibition with the anti-CTLA-4 antibody ipilimumab and the anti-PD-1 antibodies nivolumab and pembrolizumab has improved survival in metastatic melanoma, lung cancer and renal cancer. Use of these agents holds promise in other malignancies. The augmented immune response enabled by these agents has led to a particular group of side effects called immune-related adverse events (irAEs). The main irAEs include diarrhea, colitis, hepatitis, skin toxicities and endocrinopathies such as … |
| Continua a leggere |
| Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer |
| The recent approval of two PD-1 inhibitors for the treatment of non-small cell lung cancer (NSCLC) has rapidly led to the widespread use of these agents in oncology practices. Pneumonitis has been recognized as a potentially life-threatening adverse event among NSCLC patients treated with PD-1 inhibitors; however, the detailed clinical and radiographic manifestations of this entity remain to be described. We report on two cases of anti-PD-1 pneumonitis in advanced NSCLC patients treated with nivolumab after its FDA … |
| Continua a leggere |
| Immune-related adverse events with immune checkpoint blockade: a comprehensive review |
| Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells rather than cancer cells. The first generation of new immunotherapies corresponds to antagonistic antibodies that block specific immune checkpoint molecules cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand PD-L1. Targeting these checkpoints in patients living with cancer had led to long-lasting tumour … |
| Continua a leggere |
| Appuntamenti AIOM |
| XVIII CONGRESSO NAZIONALE AIOM |
| Roma, 28 – 30 ottobre 2016 |
| Link all'evento |
| IMMUNO-ONCOLOGIA Stato dell'arte e update |
| Perugia, 13 luglio 2016 Evento riservato ai Soci dell'Umbria e delle Marche |
| QUALE RAPPORTO TRA BENEFICIO E RISCHIO NELLA RE-BIOPSIA NEI PAZIENTI CON CARCINOMA POLMONARE EGFR MUTATO |
| Reggio Emilia, 20 settembre 2016 |
| VI EUROPEAN CONFERENCE ON SURVIVORS AND CHRONIC CANCER PATIENTS |
| Siracusa, 23 – 24 settembre 2016 |
| NUOVI FARMACI IN ONCOLOGIA 2016. Valore e sostenibilità |
| Ferrara, 23 settembre 2016 |
| SVILUPPI NELLA RICERCA CLINICA, DELLA NUOVA NORMATIVA EUROPEA ALLA CONDUZIONE DEGLI STUDI DI FASE I. Cosa sta cambiando? |
| Modena, 27 settembre 2016 |
| WISPO 2016 Sperimentazioni Cliniche. Il Nuovo Regolamento Europeo: dalla teoria alla pratica |
| Milano, 29 settembre 2016 |
| COMBINAZIONI E SEQUENZE IN TERAPIA: ASPETTI CLINICO-METODOLOGICI E FARMACOECONOMICI |
| Roma, 29 – 30 settembre 2016 |
| AGGIORNAMENTI NEL TRATTAMENTO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE CON MUTAZIONE DI EGFR E RIARRANGIAMENTO DI ALK |
| Brescia, 30 settembre 2016 |
| XVII CONGRESSO NAZIONALE DELLA PNEUMOLOGIA |
| Milano, 5 – 7 ottobre 2016 |
| Questi e altri appuntamenti si possono consultare sul sito AIOM www.aiom.it |
| Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI |
| Questo progetto è stato realizzato con il contributo di BMS |